A top-10 pharma company leveraged Certara’s regulatory writing services to ensure clinical data is published in a timely manner, objective, accurate, and balanced, regardless of the trial outcome.
A top-10 pharmaceutical company used Certara’s regulatory writing services to become the most transparent company in the industry.
PRINCETON, NJ – Mar. 24, 2016 – Synchrogenix has introduced an artificial intelligence (AI) -enabled solution to meet the data transparency requirements of the clinical and drug development market.
Transparency and disclosure of clinical trial data has been a hot topic, growing in prominence and strategic discussions over the past few years. Disclosing clinical trial information and creating transparency around clinical trial results are key steps toward increasing trust between the public and the industry. Increased transparency regarding data about ongoing research could spur … Continued
PRINCETON, NJ – Apr. 30, 2015 – Certara®, the global biosimulation technology-enabled drug development consultancy, today announced that its ClinGenuity company has been named a “Cool Vendor” in Gartner, Inc.’s 2015 Life Sciences report1. 2015年1月、Certaraのレギュラトリーライティング会社、SynchrogenixがClinGenuityを買収しました。“We are delighted that Gartner has recognized us,” said … Continued
The Center for Information and Study on Clinical Research Participation (CISCRP) and Synchrogenix, Certara’s regulatory writing consultancy, are collaborating to develop lay summaries of clinical trials for the general public PRINCETON, NJ – 2015年4月23日 – Certara®, the global biosimulation technology-enabled drug development consultancy and the nonprofit Center for Information and Study of Clinical … Continued
New European and U.S. clinical trial data transparency initiatives—such as EMA Policy 70, which goes into effect this month—are creating additional disclosure compliance requirements for pharma and biotech companies. In this blog post, I’ll discuss the implications of these data transparency initiatives and present how Synchrogenix, powered by ClinGenuity and a Certara company, is addressing this emerging … Continued
Deal provides Synchrogenix with proprietary technology, expert staff, and new capabilities to become the dominant player in life science regulatory and medical writing PRINCETON, NJ – Jan. 6, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that its regulatory and medical consultancy, Synchrogenix, has acquired ClinGenuity, the … Continued
